Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Canakinumab + Darbepoetin Alfa |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Canakinumab | Ilaris | ACZ-885 | Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077). | |
Darbepoetin Alfa | Aranesp | NESP|Nespo|Novel Erythropoiesis Stimulating Protein | Aranesp (darbepoetin alfa) is a recombinant analog of erythropoietin, which upon binding to the erythropoietin receptor, induces differentiation of erythroid progenitor cells into mature red blood cells (PMID: 16333460). Aranesp (darbepoetin alfa) is approved for the treatment of anemia in patients with cancer and chronic kidney disease (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04798339 | Phase Ib/II | Canakinumab + Darbepoetin Alfa | Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | Recruiting | USA | 0 |